You may be carrying one of the most significant cardiovascular risk factors in medicine — and have no idea.
Lipoprotein(a), written as Lp(a) and pronounced “LP little a,” is a genetically inherited particle in your blood that raises the risk of heart attack, stroke, and aortic valve disease — and the higher your level, the greater that risk. Elevated Lp(a) is present in roughly one in five people. It is not influenced by diet or exercise. It cannot be lowered by a statin. And most people have never been tested for it, even though U.S. guidelines now recommend testing every adult at least once.
If you’ve had a standard cholesterol panel — total cholesterol, LDL, HDL, triglycerides — you haven’t been tested for Lp(a). It is not included in routine lipid panels. In most primary care practices, it’s ordered only after a cardiac event, if at all.
That is a significant problem. Here’s why.
What Lp(a) actually is
Lp(a) is a close relative of LDL. Structurally, it consists of an LDL-like particle with an additional protein called apolipoprotein(a) attached to it. That extra protein is what makes it particularly dangerous.
In practical terms, Lp(a) promotes plaque formation in arterial walls (atherogenic), and it may also interfere with your body’s ability to break down clots (prothrombotic). Together, those effects help explain why elevated Lp(a) is associated with a substantially increased risk of early-onset heart attack and stroke — independent of LDL, blood pressure, smoking status, and all the other risk factors your doctor is probably tracking.
It is also overwhelmingly determined by genetics, and your level stays relatively stable through adult life — with one important exception for women, covered below. You can run marathons, eat a pristine diet, and maintain a healthy weight, and your Lp(a) will not meaningfully change. This is not a biomarker you can lifestyle your way out of.
Why it’s not on your standard lab panel
The short answer is historical inertia. When the standard lipid panel was developed, Lp(a) testing was expensive, not widely available, and the clinical evidence base was still developing. The framework that most physicians still use today — total cholesterol, LDL, HDL, triglycerides — was built for a different era of medicine.
The evidence since then has been decisive. Large-scale genetic studies, including Mendelian randomization analyses involving hundreds of thousands of patients, have confirmed that elevated Lp(a) is causally related to cardiovascular disease — not merely correlated with it. The European Society of Cardiology advises measuring Lp(a) at least once in every adult’s lifetime. In March 2026, the U.S. followed: the new American College of Cardiology and American Heart Association cholesterol guideline recommends measuring Lp(a) at least once in every adult — the first ACC/AHA guideline to do so.
And yet, in most annual physicals, it still isn’t ordered. The guideline has changed, but routine practice hasn’t caught up yet.
This is precisely the gap that proactive medicine exists to close.
What “elevated” actually means
Lp(a) is reported in either mg/dL or nmol/L. The two units don’t convert exactly, because Lp(a) particles vary in size, so if you can, ask for your result in nmol/L. The National Lipid Association uses three ranges:
Below 30 mg/dL (75 nmol/L): Low risk
30 to under 50 mg/dL (75 to under 125 nmol/L): Intermediate; warrants monitoring and attention to overall cardiovascular risk
50 mg/dL (125 nmol/L) or higher: Elevated; meaningfully increases cardiovascular risk and should drive more aggressive management of every other modifiable risk factor
The new U.S. guideline uses the same 50 mg/dL line to flag Lp(a) as a risk-enhancing factor, linked to about 40 percent higher cardiovascular risk. At 100 mg/dL (250 nmol/L) or higher, risk at least doubles.
Roughly 20 percent of the population falls in the elevated range. Many of them are otherwise healthy — no high blood pressure, no diabetes, no family history they’re aware of — and they have no idea this number is quietly working against them.
Why Lp(a) matters for women
Heart disease is the leading cause of death in women, and risk climbs after menopause. Yet women’s cardiovascular risk is still routinely underestimated, by patients and clinicians alike.
Lp(a) adds a wrinkle specific to women. Although your level is mostly set by your genes, women’s Lp(a) tends to rise around menopause — a shift thought to reflect falling estrogen, which normally holds Lp(a) production down. For most women the rise is modest. But when an earlier result was in the intermediate range, it can be enough to cross into the elevated range, so a result from before perimenopause may understate your level after menopause.
You may also read that hormone therapy lowers Lp(a). It does, modestly: about 20 percent on average in randomized trials, more with oral estrogen than with transdermal forms such as patches. But hormone therapy is not a treatment for elevated Lp(a), and major medical societies do not recommend it as a way to prevent heart disease. There is no evidence that the Lp(a) reduction it produces lowers the risk of heart attack or stroke. Hormone therapy is prescribed primarily to treat menopausal symptoms, and that decision rests on those symptoms, timing, and your overall risk — of which Lp(a) is one part.
What you can do if your Lp(a) is high
This is where the nuance matters, and where the conversation with a physician becomes essential.
There is currently no approved pharmacological treatment that specifically targets Lp(a), and whether lowering it with a drug prevents heart attacks is still unproven (more on that below). What elevated Lp(a) does change is the urgency and aggressiveness with which you manage every other risk factor in your cardiovascular profile.
In clinical practice, a high Lp(a) typically means:
Lower your ApoB more aggressively. ApoB is the protein carried by every atherogenic particle in the blood — one per particle, including LDL and Lp(a). When Lp(a) is elevated, bringing ApoB down substantially becomes a much higher priority. Clinicians who take a more proactive and preventive approach to heart disease often use statins, PCSK9 inhibitors, and other lipid-lowering therapies to drive ApoB below 60 mg/dL. Statins don’t lower Lp(a) itself, but they still reduce cardiovascular events and remain the foundation of treatment.
Know your coronary artery calcium (CAC) score. A CAC scan uses low-dose CT imaging to detect calcified plaque in the coronary arteries — often years or decades before a clinical event. For someone with elevated Lp(a), this provides crucial information about whether atherosclerosis has already begun developing, and calibrates treatment decisions accordingly. A calcium scan sees only calcified plaque, though, and in younger people much of the plaque may not have calcified yet. A coronary CT angiogram (CCTA) can also show soft, non-calcified plaque. It requires contrast dye and usually more radiation and isn’t a standard screening test for people without symptoms, so whether it’s worth adding is a question for your physician.
Be more aggressive about your blood pressure. Current U.S. guidelines set a goal below 130/80 for adults with high blood pressure and encourage a systolic pressure (the top number) below 120. With elevated Lp(a), reaching those goals matters even more, because when one major risk factor can’t be changed, the ones that can carry more weight, and few carry more than blood pressure.
Take your family history seriously. Because Lp(a) is genetic, a parent or sibling who had a heart attack or stroke at a young age — before 55 in a father or brother, before 65 in a mother or sister — is a significant signal, especially if they had no other obvious risk factors. First-degree relatives of someone with elevated Lp(a) should be tested.
Follow the emerging therapies, with realistic expectations. Injectable RNA-targeted drugs can lower Lp(a) by 80 percent or more. But the full results of the first large outcome trial of one of these drugs, announced in early November 2026, were a disappointment. In more than 8,000 people with high Lp(a) and existing heart disease, a drug called pelacarsen lowered Lp(a) by 78 percent. Yet over almost five years, heart attacks, strokes, and cardiovascular deaths were no less common than with placebo, even in those with the highest levels. One possible explanation is that a few years of lower Lp(a), started after heart disease has already developed, may not match the protection of naturally low levels over a lifetime. Other drugs remain in outcome trials, including one in people who haven’t had a heart attack or stroke, so at some point we may have one that lowers Lp(a) and reduces major cardiovascular events. In the meantime, none of this changes what the number tells you: Lp(a) is still an inherited, causal risk factor, and the National Lipid Association’s response to the trial was to keep measuring it.
The broader pattern: What standard medicine misses
Lp(a) is not an edge case — it’s an example of a larger pattern. Standard medicine is designed to identify and treat disease. A yearly physical checks your blood pressure, orders a basic metabolic panel and cholesterol screen, and flags anything that’s crossed a clinical threshold. If nothing is flagged, you leave with a clean bill of health.
What that model misses is the decade or two of subclinical pathology that precedes the diagnosis. Heart disease doesn’t begin with your first symptom. It begins when atherogenic particles start accumulating in arterial walls — a process that, in some people, starts in their 30s and 40s, driven by factors like Lp(a) that their physician never tested for.
This is the central argument for proactive, data-driven longevity medicine: by the time symptoms appear, the biology has already been in motion for years. The opportunity — and the leverage — is in acting early on signals, not waiting for symptoms.
Knowing your Lp(a) is one of those signals.
If you’ve never been tested
Then this is one of the easiest gaps in preventive medicine to close. Lp(a) takes a single blood draw, it can be added to routine bloodwork, and for most adults, one measurement in a lifetime is enough.
Ask whoever orders your bloodwork for:
An Lp(a) level
ApoB, if it isn’t already part of your panel
If your Lp(a) comes back elevated: a conversation about a CAC scan or CCTA, how low your ApoB and blood pressure should be, and testing for your parents, siblings, and children
If your only Lp(a) result is from before menopause: ask whether it’s worth repeating
If you’re told your cholesterol looks fine, remember that a standard panel doesn’t measure Lp(a) at all. A normal result on one test says nothing about a number no one checked.
Years of emergency medicine left me with a simple conviction: a risk factor this common, this inherited, and this easy to measure should be found on a routine lab report, not after a heart attack.
If you’d like help deciding what to test or making sense of your results, you can schedule a free discovery call.
